◎ Sugi Atlas

Atlas / Disease / Binge eating disorder

Binge eating disorder

disease
On this page

Also known as binge eating

Summary

Binge eating disorder (MONDO:0005582) is a disease with 6 cohort genes (19 GWAS associations across 9 studies) and 250 clinical trials. Top therapeutic interventions include lisdexamfetamine, solriamfetol, and bupropion.

At a glance

  • Cohort genes: 6
  • GWAS associations: 19
  • Clinical trials: 250

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namebinge eating disorder
Mondo IDMONDO:0005582
EFOEFO:0005924
MeSHD002032
ICD-10-CMF50.81
ICD-111673294767
NCITC97162
SNOMED CT439960005
UMLSC0596170
MedGen154543
Is cancer (heuristic)no

Also known as: binge eating · binge eating disorder

Data availability: 19 GWAS associations (9 studies).

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › eating disorder › binge eating disorder

Related subtypes (5): rumination disorder, pica disease, anorexia nervosa, bulimia nervosa, avoidant/restrictive food intake disorder

Genetics & variants

GWAS landscape

19 GWAS associations across 9 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs177892185e-10PRDX2P4 - SIM1C0.01
rs792200079e-10HFE, H2BC4C0.02
rs1119404291e-08LINC01789 - LINC01885T2.86
rs22750461e-08LRP11G0.01
rs7261703e-08ARHGAP8, PRR5-ARHGAP8T1.92
rs178100239e-08RPL17P25 - RPSAP72T3.85
rs79045791e-07CUBNG1.56
rs73371273e-07ATP6V1G1P7 - RPL7P45T1.75
rs1457636463e-07SLC25A26A2.08
rs74124e-07APOET0.02
rs19500387e-07LIN28AP1 - CACYBPP2T1.6
rs60068939e-07ARHGAP8, PRR5-ARHGAP8?1.99
rs101981751e-06LINC02850 - APOB?1.92
rs730574891e-06RPL7P40 - PSMC1P8C2
rs1821075831e-06MMADHC-DTC3.23
rs760876711e-06LINC01721 - GAPDHP53T2.33
rs132334904e-06NXPH1 - GAPDHP68?4.89

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90078638Backman JD202160443,660Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90082624Backman JD202160443,660Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST005386McElroy SL20183981,811Bipolar disorder with binge eating behavior: a genome-wide association study implicates PRR5-ARHGAP8.
GCST005387McElroy SL20183981,231Bipolar disorder with binge eating behavior: a genome-wide association study implicates PRR5-ARHGAP8.
GCST002419Winham SJ20142061,034Bipolar disorder with comorbid binge eating history: a genome-wide association study implicates APOB.
GCST002420Winham SJ20142060Bipolar disorder with comorbid binge eating history: a genome-wide association study implicates APOB.
GCST90328136Burstein D202300Genome-wide analysis of a model-derived binge eating disorder phenotype identifies risk loci and implicates iron metabolism.
GCST90328137Burstein D202300Genome-wide analysis of a model-derived binge eating disorder phenotype identifies risk loci and implicates iron metabolism.
GCST90328138Burstein D202300Genome-wide analysis of a model-derived binge eating disorder phenotype identifies risk loci and implicates iron metabolism.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic15

MAF distribution

BucketVariants
common (>=0.05)14
low_freq (0.01-0.05)3
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant11
intergenic_variant4
3_prime_UTR_variant1
missense_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs177892186100152221T>A,C0.25intron_variantPRDX2P4 - SIM15e-10Tier 4: intronic/intergenic
rs79220007626098246T>C0.063_prime_UTR_variantHFE, H2BC49e-10Tier 2: splice/UTR
rs1119404292107366232C>A,T0.04intron_variantLINC01789 - LINC018851e-08Tier 4: intronic/intergenic
rs22750466149835865A>C,G,T0.36intron_variantLRP111e-08Tier 4: intronic/intergenic
rs7261702244855931C>T0.12intron_variantARHGAP8, PRR5-ARHGAP83e-08Tier 4: intronic/intergenic
rs17810023680443056C>T0.02intron_variantRPL17P25 - RPSAP729e-08Tier 4: intronic/intergenic
rs79045791017089754G>A,C0.37intron_variantCUBN1e-07Tier 4: intronic/intergenic
rs733712713104623579C>A,G,T0.15intron_variantATP6V1G1P7 - RPL7P453e-07Tier 4: intronic/intergenic
rs145763646366173478G>A,T0.1intron_variantSLC25A263e-07Tier 4: intronic/intergenic
rs74121944908822C>T0.08missense_variantAPOE4e-07Tier 1: coding
rs19500382183579642T>A,C0.3intergenic_variantLIN28AP1 - CACYBPP27e-07Tier 4: intronic/intergenic
rs60068932244858015C>T0.05intron_variantARHGAP8, PRR5-ARHGAP89e-07Tier 4: intronic/intergenic
rs10198175220934123A>C,G,T0.05intergenic_variantLINC02850 - APOB1e-06Tier 4: intronic/intergenic
rs730574891217370820A>C0.07intergenic_variantRPL7P40 - PSMC1P81e-06Tier 4: intronic/intergenic
rs1821075832149675023A>C0.04intron_variantMMADHC-DT1e-06Tier 4: intronic/intergenic
rs760876712024330541C>A,G,T0.05intron_variantLINC01721 - GAPDHP531e-06Tier 4: intronic/intergenic
rs1323349079030639G>C0.05intergenic_variantNXPH1 - GAPDHP684e-06Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
SLC25A26Orphanet:466784Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect
CUBNOrphanet:35858Imerslund-Gräsbeck syndrome
APOBOrphanet:391665Homozygous familial hypercholesterolemia

Cohort genes → proteins

6 cohort genes, 5 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only6

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
SLC25A26HGNC:20661ENSG00000144741Q70HW3Mitochondrial S-adenosylmethionine carrier proteingwas
CUBNHGNC:2548ENSG00000107611O60494Cubilingwas
PRR5HGNC:31682ENSG00000186654P85299Proline-rich protein 5gwas
PER3P1HGNC:54525ENSG00000271077PER3 pseudogene 1gwas
APOBHGNC:603ENSG00000084674P04114Apolipoprotein B-100gwas
ARHGAP8HGNC:677ENSG00000241484P85298Rho GTPase-activating protein 8gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
SLC25A26Mitochondrial S-adenosylmethionine carrier proteinMitochondrial S-adenosyl-L-methionine/S-adenosyl-L-homocysteine antiporter.
CUBNCubilinEndocytic receptor which plays a role in lipoprotein, vitamin and iron metabolism by facilitating their uptake.
PRR5Proline-rich protein 5Associated subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals. mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive. mTORC2 seems to function upstream…
APOBApolipoprotein B-100Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100).
ARHGAP8Rho GTPase-activating protein 8GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 6 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown61.8×0.030

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
SLC25A26Other/UnknownnoMCP_transmembrane, MCP_dom_sf
CUBNOther/UnknownnoEGF-type_Asp/Asn_hydroxyl_site, EGF, CUB_dom
PRR5Other/UnknownnoBit61/PRR5, Cullin_repeat-like_dom_sf
PER3P1Other/Unknownno
APOBOther/UnknownnoVitellogenin_N, Lipid_transpt_open_b-sht, Lipovitellin_superhlx_dom
ARHGAP8Other/UnknownnoRhoGAP_dom, CRAL-TRIO_dom, Rho_GTPase_activation_prot

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)1
broad (>20)5
unknown0

Top tissues across cohort

TissueCohort genes
apex of heart1
gastrocnemius1
muscle of leg1
adult organism1
kidney epithelium1
nephron tubule1
adenohypophysis1
granulocyte1
spleen1
male germ line stem cell (sensu Vertebrata) in testis1
smooth muscle tissue1
sural nerve1
ileal mucosa1
jejunal mucosa1
liver1
left lobe of thyroid gland1
metanephros cortex1
right uterine tube1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
SLC25A26134ubiquitousmarkergastrocnemius, muscle of leg, apex of heart
CUBN188broadmarkeradult organism, nephron tubule, kidney epithelium
PRR5240broadmarkerspleen, adenohypophysis, granulocyte
PER3P17yesmale germ line stem cell (sensu Vertebrata) in testis, sural nerve, smooth muscle tissue
APOB116broadmarkerjejunal mucosa, liver, ileal mucosa
ARHGAP8179broadmarkerright uterine tube, metanephros cortex, left lobe of thyroid gland

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
APOB5,244
CUBN1,193
SLC25A26705
PRR5656
ARHGAP8498
PER3P10

Intra-cohort edges

ABSources
ARHGAP8PRR5string_interaction

Structural data

PDB: 2 · AlphaFold-only: 3 · No structure: 1

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
APOBP041148
CUBNO604942

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
SLC25A26Q70HW388.04
ARHGAP8P8529876.51
PRR5P8529969.59

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 58. Enrichment computed across 6 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Defective AMN causes MGA11761.3×0.017CUBN
Defective CUBN causes MGA11761.3×0.017CUBN
Scavenging by Class H Receptors1571.0×0.017APOB
VLDL assembly1456.8×0.017APOB
HDL clearance1456.8×0.017CUBN
Chylomicron clearance1456.8×0.017APOB
Scavenging by Class F Receptors1380.7×0.017APOB
LDL remodeling1380.7×0.017APOB
VLDL clearance1380.7×0.017APOB
Chylomicron assembly1228.4×0.021APOB
Chylomicron remodeling1228.4×0.021APOB
Uptake of dietary cobalamins into enterocytes1228.4×0.021CUBN
Scavenging by Class B Receptors1207.6×0.021APOB
Vitamin D (calciferol) metabolism1175.7×0.024CUBN
SLC-mediated transport of organic cations1152.3×0.024SLC25A26
Plasma lipoprotein assembly1142.8×0.024APOB
Dengue virus modulates apoptosis1142.8×0.024PRR5
Platelet sensitization by LDL1134.3×0.024APOB
Scavenging by Class A Receptors1120.2×0.025APOB
Binding and Uptake of Ligands by Scavenger Receptors1108.8×0.025APOB
LDL clearance1108.8×0.025APOB
Regulation of TLR by endogenous ligand199.3×0.025APOB
Plasma lipoprotein remodeling195.2×0.025APOB
Plasma lipoprotein clearance195.2×0.025APOB
Constitutive Signaling by AKT1 E17K in Cancer184.6×0.027PRR5
VEGFR2 mediated vascular permeability181.6×0.027PRR5
CD28 dependent PI3K/Akt signaling178.8×0.027PRR5
Metabolism of fat-soluble vitamins176.1×0.027APOB
Transport of small molecules210.1×0.029SLC25A26, APOB
Regulation of TP53 Degradation158.6×0.033PRR5

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
lipoprotein transport2396.5×4e-04CUBN, APOB
S-adenosyl-L-methionine transport13370.4×0.003SLC25A26
macromolecule methylation13370.4×0.003SLC25A26
mitochondrial S-adenosyl-L-methionine transmembrane transport13370.4×0.003SLC25A26
cholesterol metabolic process278.4×0.003CUBN, APOB
establishment of localization in cell264.2×0.003CUBN, APOB
negative regulation of endocytic recycling11123.5×0.006ARHGAP8
triglyceride mobilization1842.6×0.007APOB
cellular response to lipoprotein particle stimulus1674.1×0.008APOB
lipoprotein biosynthetic process1561.7×0.008APOB
positive regulation of cholesterol storage1481.5×0.008APOB
lipoprotein catabolic process1481.5×0.008APOB
cobalamin transport1374.5×0.010CUBN
cobalamin metabolic process1306.4×0.010CUBN
TORC2 signaling1306.4×0.010PRR5
regulation of cholesterol biosynthetic process1306.4×0.010APOB
positive regulation of lipid storage1280.9×0.010APOB
very-low-density lipoprotein particle assembly1240.7×0.011APOB
low-density lipoprotein particle remodeling1210.7×0.012APOB
low-density lipoprotein particle clearance1198.3×0.012APOB
positive regulation of macrophage derived foam cell differentiation1168.5×0.013APOB
triglyceride catabolic process1160.5×0.013APOB
cholesterol transport1146.5×0.014APOB
artery morphogenesis1134.8×0.014APOB
tissue homeostasis1112.3×0.017CUBN
cholesterol efflux1105.3×0.017APOB
cellular response to nutrient levels193.6×0.019PRR5
fertilization162.4×0.027APOB
receptor-mediated endocytosis144.4×0.036CUBN
phosphatidylinositol 3-kinase/protein kinase B signal transduction142.1×0.037PRR5

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
TopiramatePhase 3
DrospirenonePhase 2
Ethinyl EstradiolPhase 2

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 6

Druggability breadth: 1 of 6 evidence-associated genes (17%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
SLC25A2600
CUBN00
PRR500
PER3P100
APOB00
ARHGAP800

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
APOB1Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug6SLC25A26, CUBN, PRR5, PER3P1, APOB, ARHGAP8

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
SLC25A260—
CUBN0—
PRR50—
PER3P10—
APOB1—
ARHGAP80—

Clinical trials & evidence

Clinical trials

Clinical trials: 250.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified183
PHASE218
PHASE317
PHASE2/PHASE314
PHASE47
PHASE1/PHASE24
PHASE14
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00327834PHASE4COMPLETEDAtomoxetine in the Treatment of Binge Eating Disorder
NCT00330655PHASE4COMPLETEDAn Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
NCT00516919PHASE4COMPLETEDStudy of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
NCT00537810PHASE4COMPLETEDTreatment of Binge Eating in Obese Patients in Primary Care
NCT00607789PHASE4COMPLETEDStudy of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression
NCT04602936PHASE4UNKNOWNSolriamfetol in Binge Eating Disorder
NCT05560529PHASE4COMPLETEDDialectical Behavioral Therapy As A Therapeutic Tool In Patients With Binge Eating Disorder
NCT06413433PHASE3RECRUITINGElucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06878976PHASE3ENROLLING_BY_INVITATIONOpen-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
NCT00032760PHASE2/PHASE3COMPLETEDMeditation-Based Treatment for Binge Eating Disorder
NCT00210808PHASE2/PHASE3COMPLETEDA Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
NCT00277641PHASE3COMPLETEDLamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
NCT00307619PHASE3COMPLETEDAn Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.
NCT00402584PHASE3COMPLETEDA Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
NCT00414167PHASE2/PHASE3COMPLETEDCraving, Binge Eating and Obesity
NCT00511940PHASE2/PHASE3COMPLETEDAcamprosate in the Treatment of Binge-Eating Disorder
NCT00514995PHASE2/PHASE3COMPLETEDSodium Oxybate in the Treatment of Binge Eating Disorder
NCT01010789PHASE3COMPLETEDArmodafinil in Binge Eating Disorder (BED)
NCT01090713PHASE3COMPLETEDEfficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder
NCT01106053PHASE3WITHDRAWNPramipexole for Binge Eating Disorder
NCT01567670PHASE2/PHASE3UNKNOWNClinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray
NCT01657019PHASE3COMPLETEDOpen Label Extension in Adults With Binge Eating Disorder (BED)
NCT01693237PHASE2/PHASE3UNKNOWNImproving Patient Outcome in Group Therapy for Eating Disorders
NCT01718483PHASE3COMPLETEDSPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
NCT01718509PHASE3COMPLETEDSPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
NCT02009163PHASE3COMPLETEDEvaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
NCT02564588PHASE2/PHASE3COMPLETEDDasotraline Binge Eating Disorder Study
NCT02684279PHASE3COMPLETEDDasotraline Binge Eating Disorder Extension Study
NCT03045341PHASE2/PHASE3COMPLETEDBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
NCT03047005PHASE2/PHASE3COMPLETEDBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
NCT03063606PHASE2/PHASE3COMPLETEDBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
NCT03107026PHASE3COMPLETEDA Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
NCT03279731PHASE3TERMINATEDBinge Eating Liraglutide Intervention
NCT03539900PHASE2/PHASE3COMPLETEDEfficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder
NCT03717493PHASE2/PHASE3COMPLETEDDeficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder
NCT03924193PHASE3COMPLETEDCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
NCT03926052PHASE3COMPLETEDCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
NCT03946111PHASE2/PHASE3COMPLETEDCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
NCT05664516PHASE2RECRUITINGA Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
NCT06817863PHASE1/PHASE2RECRUITINGA Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
LISDEXAMFETAMINE49
SOLRIAMFETOL49
BUPROPION47
ATOMOXETINE43
OXYBATE43
PHENTERMINE43
SIBUTRAMINE43
ORLISTAT42
TOPIRAMATE42
ACAMPROSATE41
ARMODAFINIL41
DULOXETINE41
LAMOTRIGINE41
MEMANTINE41
NALOXONE41
PRAMIPEXOLE41
VORTIOXETINE41
DASOTRALINE33
CENTANAFADINE31
DEXPRAMIPEXOLE31
GHRELIN31
MIDOMAFETAMINE31
GLP-121
CHROMIUM PICOLINATE11
GLUCAGON-LIKE PEPTIDE 111
CHEMBL422798003
CHEMBL42528101
CHEMBL541032401
CHEMBL120134301
CHEMBL422757301

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 70

This page pulls from 70 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot